A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)

Part of paid clinical trials in Fairhope, Alabama.

Sponsor
Colorado Prevention Center
Study ID
NCT06024746
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.

Key Dates

Start date
Jul 9, 2024
Status verified
Mar 2025
Primary completion
Jul 31, 2026
Completion
Aug 31, 2026

Study Design

Enrollment
1,500 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Finerenone plus empagliflozin
  • No Intervention: Usual care
    Usual care management

Primary Outcome Measure

Clinical benefit [ Time Frame: 6 months ]

Central Contacts

Locations (8)

FacilityCityStateZIPSite coordinators
CON-10004 Fairhope, AL Investigational SiteFairhopeAlabama36532-
CON-10075 El Centro, CA Investigational SiteEl CentroCalifornia92243-
CON-10024 Sacramento, CA Investigational SiteSacramentoCalifornia95816-
CON-10022 Atlanta, GA Investigational SiteAtlantaGeorgia30303-
CON-10030 Baton Rouge, LA Investigational SiteBaton RougeLouisiana70808-
CON-10002 Kansas City, MO Investigative SiteKansas CityMissouri64111
Marc Bonaca
CON-10045 Amarillo, TX Investigational SiteAmarilloTexas79106-
CON-10015 Austin, TX Investigational SiteAustinTexas78705-

Find similar trials in Fairhope, AL

By condition
Heart failure
By specialty
CardiologyHeart disease
By research site
CON-10004 Fairhope, AL Investigational Site· Fairhope, ALCON-10075 El Centro, CA Investigational Site· El Centro, CACON-10024 Sacramento, CA Investigational Site· Sacramento, CACON-10022 Atlanta, GA Investigational Site· Atlanta, GACON-10030 Baton Rouge, LA Investigational Site· Baton Rouge, LACON-10002 Kansas City, MO Investigative Site· Kansas City, MO

Related Studies